Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Trial Identifier: 3475-03A
Sponsor: MSD
Start Date: December 2020
Primary Completion Date: May 2026
Study Completion Date: May 2026
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary
Protocol Plain Language Summary

Trial Locations